Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Therapeutic angiogenesis in cardiology using protein formulations
Autore:
Post, MJ; Laham, R; Sellke, FW; Simons, M;
Indirizzi:
Beth Israel Deaconess Med Ctr, Angiogenesis Res Ctr, Harvard Med Sch, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr Boston MA USA 02215 h, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr, Div Cardiothorac Surg, Harvard Med Sch, FWS, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr Boston MA USA 02215 S, Boston, MA 02215 USA
Titolo Testata:
CARDIOVASCULAR RESEARCH
fascicolo: 3, volume: 49, anno: 2001,
pagine: 522 - 531
SICI:
0008-6363(20010216)49:3<522:TAICUP>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
FIBROBLAST-GROWTH-FACTOR; CORONARY-ARTERY DISEASE; CHRONIC MYOCARDIAL-ISCHEMIA; ENDOTHELIAL PROGENITOR CELLS; COLLATERAL BLOOD-FLOW; GENE-TRANSFER; PORCINE MODEL; HEART-DISEASE; TRANSMYOCARDIAL REVASCULARIZATION; INFARCTED MYOCARDIUM;
Keywords:
angiogenisis; coronory disease;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
120
Recensione:
Indirizzi per estratti:
Indirizzo: Post, MJ Beth Israel Deaconess Med Ctr, Angiogenesis Res Ctr, Harvard Med Sch, RoomSL 423,330 Brookline Ave, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr Room SL 423,330 Brookline Ave Boston MA USA 02215
Citazione:
M.J. Post et al., "Therapeutic angiogenesis in cardiology using protein formulations", CARDIO RES, 49(3), 2001, pp. 522-531

Abstract

Therapeutic angiogenesis in cardiovascular disease aims at improving myocardial function by increasing blood How to ischemic myocardium that is not amenable to traditional forms of revascularization. preclinical data have provided proof of the concept that angiogenic growth factors such as fibroblast growth factor 2 (FGF-2) and vascular endothelium growth factor (VEGF) may indeed improve myocardial flow and function when administered in ways that ensure prolonged tissue exposure to these short-lived molecules. Althoughother cytokines have been shown to enhance angiogenesis in vivo, FGF-2 andVEGF have been most widely studied and may serve as prototype proangiogenic drugs. Currently, several delivery techniques that are clinically applicable are being studied with respect to tissue distribution and retention as well as angiogenic efficacy of FGF-2 and VEGF. Although tissue distributionand retention of FGF-2 after intramyocardial injection compares favorably with other routes of administration, efficacy studies are not yet conclusive. At the same time, different protein- and gene-based formulations are being investigated. Arguments for and against protein and gene therapy are presented, showing that protein-based therapy seems to have advantages over gene therapy Lit the present time. although continuous efforts should be madeto increase the tissue exposure time after a single administration of protein. While delivery systems and growth factor formulations are being improved. double-blind, placebo-controlled trials designed with existing animal data in mind, are needed to firmly establish the utility of therapeutic angiogenesis in cardiovascular disease. (C) 2001 Elsevier Science B.V. AII rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 11:58:33